Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

Morice, 2002, A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N Engl J Med, 346, 1773, 10.1056/NEJMoa012843

Moses, 2003, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery, N Engl J Med, 349, 1315, 10.1056/NEJMoa035071

Stone, 2004, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease, N Engl J Med, 350, 221, 10.1056/NEJMoa032441

Stone, 2005, Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial, Jama, 294, 1215, 10.1001/jama.294.10.1215

Ong, 2005, The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry, J Am Coll Cardiol, 45, 1135, 10.1016/j.jacc.2005.01.008

Windecker, 2005, Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization, N Engl J Med, 353, 653, 10.1056/NEJMoa051175

Lemos, 2004, Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry, Circulation, 109, 190, 10.1161/01.CIR.0000109138.84579.FA

Kaiser, 2005, Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET), Lancet, 366, 921, 10.1016/S0140-6736(05)67221-2

Farb, 1999, Pathology of acute and chronic coronary stenting in humans, Circulation, 99, 44, 10.1161/01.CIR.99.1.44

Joner, 2006, Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J Am Coll Cardiol, 48, 193, 10.1016/j.jacc.2006.03.042

Nilsen, 2006, Late complications following the deployment of drug eluting stents, Int J Cardiol, 109, 398, 10.1016/j.ijcard.2005.05.029

Virmani, 2004, Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?, Circulation, 109, 701, 10.1161/01.CIR.0000116202.41966.D4

Nebeker, 2006, Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project, J Am Coll Cardiol, 47, 175, 10.1016/j.jacc.2005.07.071

Togni, 2005, Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction, J Am Coll Cardiol, 46, 231, 10.1016/j.jacc.2005.01.062

Hofma, 2006, Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation, Eur Heart J, 27, 166, 10.1093/eurheartj/ehi571

Wenaweser, 2005, Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome, Eur Heart J, 26, 1180, 10.1093/eurheartj/ehi135

Babapulle, 2004, A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents, Lancet, 364, 583, 10.1016/S0140-6736(04)16850-5

Moreno, 2005, Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies, J Am Coll Cardiol, 45, 954, 10.1016/j.jacc.2004.11.065

Ong, 2005, Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation, J Am Coll Cardiol, 45, 947, 10.1016/j.jacc.2004.09.079

Bavry, 2005, What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis, J Am Coll Cardiol, 45, 941, 10.1016/j.jacc.2004.11.064

Roiron, 2006, Drug eluting stents: an updated meta-analysis of randomised controlled trials, Heart, 92, 641, 10.1136/hrt.2005.061622

Leon, 2006, Late stent thrombosis in sirolimus-eluting versus bare metal stents in 4 randomized clinical trials with 3-year follow-up, J Am Coll Cardiol, 47

McFadden, 2004, Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy, Lancet, 364, 1519, 10.1016/S0140-6736(04)17275-9

Rodriguez, 2006, Revascularization strategies of coronary multivessel disease in the drug-eluting stent era: one year follow-up results of the ERACI-III trial, Euro Intervention, 2, 53

Lee, 2006, Late angiographic stent thrombosis of polymer based paclitaxel eluting stent, Heart, 92, 551, 10.1136/hrt.2005.073619

Iakovou, 2005, Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents, JAMA, 293, 2126, 10.1001/jama.293.17.2126

Kuchulakanti, 2006, Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents, Circulation, 113, 1108, 10.1161/CIRCULATIONAHA.105.600155

Urban, 2006, Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry, Circulation, 113, 1434, 10.1161/CIRCULATIONAHA.104.532242

Lemos, 2003, Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry, J Am Coll Cardiol, 41, 2093, 10.1016/S0735-1097(03)00429-7

Colombo, 2003, Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions, Circulation, 108, 788, 10.1161/01.CIR.0000086926.62288.A6

Lincoff, 1999, Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators, N Engl J Med, 341, 319, 10.1056/NEJM199907293410503

Braunwald, 2000, J Am Coll Cardiol, 36, 970, 10.1016/S0735-1097(00)00889-5

Glynn, 1996, Ways of measuring rates of recurrent events, BMJ, 312, 364, 10.1136/bmj.312.7027.364

Tapia Granados, 1997, On the terminology and dimensions of incidence, J Clin Epidemiol, 50, 891, 10.1016/S0895-4356(97)00105-4

Ong, 2005, Late angiographic stent thrombosis (LAST) events with drug-eluting stents, J Am Coll Cardiol, 45, 2088, 10.1016/j.jacc.2005.02.086

Sabate, 2005, Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial, Circulation, 112, 2175, 10.1161/CIRCULATIONAHA.105.562421

Stone, 2006

Kotani, 2006, Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings, J Am Coll Cardiol, 47, 2108, 10.1016/j.jacc.2005.11.092

Honda, 2003, Stent thrombosis: an issue revisited in a changing world, Circulation, 108, 2, 10.1161/01.CIR.0000075929.79964.D8

Park, 2006, Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up, Am J Cardiol, 98, 352, 10.1016/j.amjcard.2006.02.039

West, 2004, Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients, Circulation, 109, 867, 10.1161/01.CIR.0000116750.63158.94

Niles, 2001, Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study, J Am Coll Cardiol, 37, 1008, 10.1016/S0735-1097(00)01205-5

Lincoff, 2003, Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade, Circulation, 107, 1556, 10.1161/01.CIR.0000055653.52489.E9

Aronson, 1996, Potential mechanisms promoting restenosis in diabetic patients, J Am Coll Cardiol, 27, 528, 10.1016/0735-1097(95)00496-3

Zeiher, 1995, Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function, Circulation, 92, 1094, 10.1161/01.CIR.92.5.1094

Celermajer, 1993, Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults, Circulation, 88, 2149, 10.1161/01.CIR.88.5.2149

Barbash, 1993, Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial, Circulation, 87, 53, 10.1161/01.CIR.87.1.53

Violaris, 2000, Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty, Heart, 84, 299, 10.1136/heart.84.3.299

Perin, 2005, Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS, Rev Cardiovasc Med, 6, S13

Levin, 2004, Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel, Proc Natl Acad Sci U S A, 101, 9463, 10.1073/pnas.0400918101

Rogers, 2005, Drug-eluting stents: clinical perspectives on drug and design differences, Rev Cardiovasc Med, 6, S3

Wenaweser, 2005, Stent thrombosis is associated with an impaired response to antiplatelet therapy, J Am Coll Cardiol, 45, 1748, 10.1016/j.jacc.2005.01.058

Gurbel, 2005, Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study, J Am Coll Cardiol, 46, 1827, 10.1016/j.jacc.2005.07.056

Kaluza, 2000, Catastrophic outcomes of noncardiac surgery soon after coronary stenting, J Am Coll Cardiol, 35, 1288, 10.1016/S0735-1097(00)00521-0

Blais, 1996, Confounding by indication and channeling over time: the risks of beta 2-agonists, Am J Epidemiol, 144, 1161, 10.1093/oxfordjournals.aje.a008895

Ioannidis, 2004, Better reporting of harms in randomized trials: an extension of the CONSORT statement, Ann Intern Med, 141, 781, 10.7326/0003-4819-141-10-200411160-00009